Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.

Breast Cancer · 2026 · PMC12960296 · PMID 41670927

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Even after this analysis, patients who started at 125 mg still showed a trend toward better outcomes, supporting the appropriateness of this starting dose in selected elderly patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.